Eco Animal Health Group PLC Revised Notice of Results (6926W)
22 August 2022 - 4:00PM
UK Regulatory
TIDMEAH
RNS Number : 6926W
Eco Animal Health Group PLC
22 August 2022
22 August 2022
ECO Animal Health Group plc
("ECO", the "Company" or the "ECO Group") (AIM: EAH)
REVISED NOTICE OF RESULTS
ECO Animal Health Group plc, a leader in the development,
registration and marketing of pharmaceutical products for global
animal health markets, today announces a revised date for the
publication of its preliminary results for the year ended 31 March
2022.
The Company's auditor, BDO LLP, has requested additional time to
complete its audit completion procedures. As a result, the Company
now expects to announce its final results on 31 August 2022.
As previously announced in the trading update on 8 August 2022,
the Group expects to report full-year results for the year ended 31
March 2022 with revenue of approximately GBP82.2 million (2021:
GBP105.6 million) and an EBITDA of approximately GBP6.4 million
which includes an exchange rate gain of GBP1.0 million.
The information contained within this announcement is deemed by
the Group to constitute inside information as stipulated under the
Market Abuse Regulations (EU) No. 596/2014 ("MAR") as it forms part
of United Kingdom domestic law by virtue of the European Union
(Withdrawal) Act 2018. Upon the publication of this announcement
via a Regulatory Information Service ("RIS"), this inside
information is now considered to be in the public domain.
For further information please contact:
ECO Animal Health Group plc
David Hallas (CEO)
Christopher Wilks (CFO) 020 8447 8899
IFC Advisory
Graham Herring
Zach Cohen 020 3934 6630
Singer Capital Markets (Nominated Adviser
& Joint Broker)
Mark Taylor
George Tzimas 020 7496 3000
Investec (Joint Broker)
Gary Clarence
Brough Ransom 020 7597 5970
Carlo Spingardi
Peel Hunt LLP (Joint Broker)
Dr Christopher Golden
James Steel 020 7418 8900
Equity Developments
Hannah Crowe
Matt Evans 020 7065 2692
About ECO Animal Health
ECO Animal Health Group plc researches, develops and
commercialises products for livestock. Our business strategy is to
generate shareholder value by achieving the maximum sales potential
from the existing product portfolio whilst investing in Research
and Development ("R&D") for new products, particularly
vaccines, and seeking to in-license new products.
END
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORBRGDIDBDDGDB
(END) Dow Jones Newswires
August 22, 2022 02:00 ET (06:00 GMT)
Eco Animal Health (LSE:EAH)
Historical Stock Chart
From Sep 2024 to Oct 2024
Eco Animal Health (LSE:EAH)
Historical Stock Chart
From Oct 2023 to Oct 2024